Literature DB >> 9118031

Correlation of hepatitis virus serologic status with clinicopathologic features in patients undergoing hepatectomy for hepatocellular carcinoma.

N Yamanaka1, T Tanaka, W Tanaka, J Yamanaka, C Yasui, N Kuroda, M Takada, E Okamoto.   

Abstract

BACKGROUND: This study investigated the relationship between clinicopathologic features and various viral serologies in patients who underwent hepatectomy in the treatment of hepatocellular carcinoma (HCC).
METHODS: Two hundred two patients were allocated to four groups, according to their positivity or negativity for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCVAb): Group I (HBsAg[-], HCVAb[+], n = 151), Group II (HBsAg[+], HCVAb[-], n = 27), Group III (HBsAg[-], HCVAb[-], n = 20), or Group IV (HBsAg[+], HCVAb[-], n = 4). The mean age of the HBsAg positive patients (Groups II and IV) was 10 years younger than that of the HBsAg negative patients (Groups I and III).
RESULTS: The male-to-female ratio was higher in HCVAb negative groups (II and III). The HCVAb positive groups (I and IV) had a significantly poorer hepatic reserve and smaller resections than the HCVAb negative groups. Because the tumors were more advanced (as determined by TNM staging) in Group II, the 3-year crude and disease free survival rates were lower in Group II than in Group I. However, HCVAb negative groups (II and III), when compared at 5 years with the limited subsets of patients who had tumors at earlier stages or a curative resection, had significantly better crude and disease free 5-year survival rates than the HCVAb positive group (I).
CONCLUSIONS: Clinicopathologic features differ from one another in accordance with the viral seromarkers in HCC patients. Significantly better crude and disease free survival after complete resection were promising results for patients with non-HCV-related HCC. By comparison, for patients with HCV-related HCC, the risk of intrahepatic recurrences never subsided even in later years after complete resection. Therefore, posthepatectomy follow-up management should be individualized depending on the viral serologic status of HCC patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9118031     DOI: 10.1002/(sici)1097-0142(19970415)79:8<1509::aid-cncr10>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  27 in total

1.  Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Pavel Vladimirovich Korita; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

Review 2.  Glycosylation and liver cancer.

Authors:  Anand Mehta; Harmin Herrera; Timothy Block
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Actual 10-year survival following hepatectomy for hepatocellular carcinoma.

Authors:  Bernardo Franssen; Ghalib Jibara; Parissa Tabrizian; Myron E Schwartz; Sasan Roayaie
Journal:  HPB (Oxford)       Date:  2013-12-24       Impact factor: 3.647

4.  Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma.

Authors:  Nader N Massarweh; James O Park; Farhood Farjah; Raymond S W Yeung; Rebecca Gaston Symons; Thomas L Vaughan; Laura-Mae Baldwin; David R Flum
Journal:  J Am Coll Surg       Date:  2010-04       Impact factor: 6.113

5.  Prognostic value of thymidine phosphorylase activity in liver tissue adjacent to hepatocellular carcinoma.

Authors:  Takahiro Ezaki; Toru Ikegami; Takashi Maeda; Tomomi Yamada; Teruyoshi Ishida; Makoto Hashizume; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2005-06       Impact factor: 3.402

6.  Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence.

Authors:  Giorgio Ercolani; Gian Luca Grazi; Matteo Ravaioli; Massimo Del Gaudio; Andrea Gardini; Matteo Cescon; Giovanni Varotti; Francesco Cetta; Antonino Cavallari
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

7.  Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma.

Authors:  Yo Sasaki; Terumasa Yamada; Hideo Tanaka; Hiroaki Ohigashi; Hidetoshi Eguchi; Masahiko Yano; Osamu Ishikawa; Shingi Imaoka
Journal:  Ann Surg       Date:  2006-11       Impact factor: 12.969

8.  Influence of higher BMI for hepatitis B- and C-related hepatocellular carcinomas.

Authors:  Masakazu Hashimoto; Hirotaka Tashiro; Tsuyoshi Kobayashi; Shintaro Kuroda; Michinori Hamaoka; Hideki Ohdan
Journal:  Langenbecks Arch Surg       Date:  2017-05-22       Impact factor: 3.445

9.  Significance of HBV DNA in the hepatic parenchyma from patients with non-B, non-C hepatocellular carcinoma.

Authors:  Takuya Nakai; Osamu Shiraishi; Takashi Kawabe; Hideo Ota; Hiroaki Nagano; Hitoshi Shiozaki
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

10.  Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection.

Authors:  Jeong Won Lee; Sang Hyun Hwang; Hyun Jeong Kim; Dongwoo Kim; Arthur Cho; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-11       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.